Hikma Pharmaceuticals (LSE:HIK), the London-listed generics-to-injectables group with deep roots in the Middle East, delivered a first half its chief executive called "solid" rather than spectacular. Group revenue rose 4% to $1.73 billion and core operating profit climbed 9% to $405 million in the …
HSBC's downgrade wasn't a routine trim. The bank had been one of AstraZeneca's more bullish voices, and its retreat to Hold — alongside a price-target cut of roughly 17% — signalled genuine unease rather than box-ticking caution. The note argued that AstraZeneca's path to …
Allergy Therapeutics LSE:AGY has attracted renewed investor attention on 10 August 2026 after recording a9.09% gain.
CRISM Therapeutics LSE:CRTX has recorded an8.42% gain on 10 August 2026, putting the stock firmly into focus among UK healthcare and biotechnology shares.
Proteome Sciences LSE:PRM has attracted renewed market attention on 10 August 2026 after recording an11.11% gain.
AstraZeneca (LSE:AZN) has spent the past fortnight at the centre of the pharmaceutical industry's biggest rumour in years. Reports that Britain's most valuable listed company was discussing a near-$400 billion combination with US rival Bristol Myers Squibb sent its shares into their steepest one-day …
The AIM-listed epigenetics group has signed its first commercial agreement for the EpiSwitch Orion data platform and landed a US sales partnership, but interim results reveal cash of just £1.38m and a stated need for fresh funds by late August 2026.
AIM-listed Shield Therapeutics says it stayed profitable through the first half of 2026, with revenue up sharply to $30.4m. A Chinese milestone payment flattered the numbers, and US pricing pressure on its iron-deficiency drug ACCRUFeR bears close watching.
The AIM-listed lateral flow diagnostics specialist reported revenue up 37% to £4.2 million in the six months to December 2025, narrowed its EBITDA loss, and told investors it expects the second half of its financial year to turn EBITDA and cash-flow positive.
AIM-listed Arecor Therapeutics has collected the first commercial milestone under its royalty deal with Ligand Pharmaceuticals, a modest but symbolic step as the group leans on non-dilutive cash to fund its ultra-concentrated insulin programme through 2027.